Plasma thiopurine S-methyltransferase levels and azathioprine-related adverse events in patients with Behçet's disease
OBJECTIVES: Thiopurine S-methyltransferase (TPMT) is the key enzyme inactivating azathioprine (AZA), an immunosuppressive agent commonly used for treating inflammatory diseases including Behçet's disease (BD), systemic lupus erythematosus (SLE) and systemic vasculitis. Low TPMT levels facilitate occurrence of AZA-related adverse effects. We investigated TPMT levels in patients with BD, compared to healthy controls and patients with SLE or systemic vasculitis.
METHODS: This cross-sectional study included 101 BD (77 using AZA), 74 SLE (35 using AZA), and 44 vasculitis (18 using AZA) patients and 101 healthy controls. Plasma TPMT levels were measured using ELISA. Student's t- and Kruskal-Wallis tests were used to compare TPMT levels according to possible risk factors. Receiver operating characteristic (ROC) analysis was used to determine whether a cut-off TPMT level could be found to predict AZA-related adverse effects.
RESULTS: Plasma TPMT levels (mean± SD ng/mL) in BD (22.80±13.81) were comparable with healthy controls (22.71±13.49), but significantly lower than in SLE group (29.37±11.39) (p<0.001). TPMT levels in 130 patients receiving AZA were similar to the rest of the group. AZA-related adverse effects were identified in only 8 patients (5 with BD and 3 with SLE). TPMT levels were significantly lower in those 8 patients (14.08±9.49 vs. 25.62±12.68) (p=0.013), besides a cut-off value for predicting adverse effects was determined for the BD group with ROC analysis (area under the curve: 0.813).
CONCLUSIONS: This is the first study to evaluate TPMT activity in a Turkish adult population. Although low plasma TPMT level is not the only factor determining AZA toxicity, a TPMT cut-off value may help to predict AZA-related adverse effects in BD.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Clinical and experimental rheumatology - 33(2015), 6 Suppl 94 vom: 21. Nov., Seite S40-5 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Emmungil, Hakan [VerfasserIn] |
|---|
| Themen: |
Azathioprine |
|---|
| Anmerkungen: |
Date Completed 14.01.2016 Date Revised 12.01.2017 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM248644297 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM248644297 | ||
| 003 | DE-627 | ||
| 005 | 20231224151843.0 | ||
| 007 | tu | ||
| 008 | 231224s2015 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0828.xml |
| 035 | |a (DE-627)NLM248644297 | ||
| 035 | |a (NLM)25936353 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Emmungil, Hakan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma thiopurine S-methyltransferase levels and azathioprine-related adverse events in patients with Behçet's disease |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 14.01.2016 | ||
| 500 | |a Date Revised 12.01.2017 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: Thiopurine S-methyltransferase (TPMT) is the key enzyme inactivating azathioprine (AZA), an immunosuppressive agent commonly used for treating inflammatory diseases including Behçet's disease (BD), systemic lupus erythematosus (SLE) and systemic vasculitis. Low TPMT levels facilitate occurrence of AZA-related adverse effects. We investigated TPMT levels in patients with BD, compared to healthy controls and patients with SLE or systemic vasculitis | ||
| 520 | |a METHODS: This cross-sectional study included 101 BD (77 using AZA), 74 SLE (35 using AZA), and 44 vasculitis (18 using AZA) patients and 101 healthy controls. Plasma TPMT levels were measured using ELISA. Student's t- and Kruskal-Wallis tests were used to compare TPMT levels according to possible risk factors. Receiver operating characteristic (ROC) analysis was used to determine whether a cut-off TPMT level could be found to predict AZA-related adverse effects | ||
| 520 | |a RESULTS: Plasma TPMT levels (mean± SD ng/mL) in BD (22.80±13.81) were comparable with healthy controls (22.71±13.49), but significantly lower than in SLE group (29.37±11.39) (p<0.001). TPMT levels in 130 patients receiving AZA were similar to the rest of the group. AZA-related adverse effects were identified in only 8 patients (5 with BD and 3 with SLE). TPMT levels were significantly lower in those 8 patients (14.08±9.49 vs. 25.62±12.68) (p=0.013), besides a cut-off value for predicting adverse effects was determined for the BD group with ROC analysis (area under the curve: 0.813) | ||
| 520 | |a CONCLUSIONS: This is the first study to evaluate TPMT activity in a Turkish adult population. Although low plasma TPMT level is not the only factor determining AZA toxicity, a TPMT cut-off value may help to predict AZA-related adverse effects in BD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Methyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.1.1.- |2 NLM | |
| 650 | 7 | |a thiopurine methyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.1.1.67 |2 NLM | |
| 650 | 7 | |a Azathioprine |2 NLM | |
| 650 | 7 | |a MRK240IY2L |2 NLM | |
| 700 | 1 | |a Durusoy, Raika |e verfasserin |4 aut | |
| 700 | 1 | |a Kalfa, Melike |e verfasserin |4 aut | |
| 700 | 1 | |a Yargucu Zihni, Figen |e verfasserin |4 aut | |
| 700 | 1 | |a Özmen, Mustafa |e verfasserin |4 aut | |
| 700 | 1 | |a Keser, Gökhan |e verfasserin |4 aut | |
| 700 | 1 | |a Gücenmez, Sercan |e verfasserin |4 aut | |
| 700 | 1 | |a Yilmaz, Zevcet |e verfasserin |4 aut | |
| 700 | 1 | |a Aksu, Kenan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental rheumatology |d 1989 |g 33(2015), 6 Suppl 94 vom: 21. Nov., Seite S40-5 |w (DE-627)NLM012613010 |x 0392-856X |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2015 |g number:6 Suppl 94 |g day:21 |g month:11 |g pages:S40-5 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2015 |e 6 Suppl 94 |b 21 |c 11 |h S40-5 | ||